SAHLTECH AB has a total of 54 patent applications. Its first patent ever was published in 1994. It filed its patents most often in Sweden, WIPO (World Intellectual Property Organization) and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are BERG LLC, CAO LIANGXIAN and UNIV CANBERRA.
# | Country | Total Patents | |
---|---|---|---|
#1 | Sweden | 20 | |
#2 | WIPO (World Intellectual Property Organization) | 20 | |
#3 | EPO (European Patent Office) | 14 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement | |
#4 | Machines | |
#5 | Micro-structure and nano-technology |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Analysing materials | |
#4 | Peptides | |
#5 | Measuring microorganism processes | |
#6 | Unspecified technologies | |
#7 | Microorganisms | |
#8 | Nanostructure applications |
# | Name | Total Patents |
---|---|---|
#1 | Isgaard Joergen | 9 |
#2 | Jansson John-Olov | 8 |
#3 | Tarkowski Andrej | 8 |
#4 | Norstedt Gunnar | 8 |
#5 | Wallenius Ville | 7 |
#6 | Johannsson Gudmundur | 6 |
#7 | Bengtsson Bengt-Aake | 5 |
#8 | Verdrengh Margareta | 4 |
#9 | Rudling Mats | 3 |
#10 | Omerovic Elmir | 3 |
Publication | Filing date | Title |
---|---|---|
EP2085407A1 | Treatment of idiopathic thrombocytopenic purpura | |
EP1716887A1 | Treatment of inclusion body myositis | |
EP1577674A1 | Recombinant human tsh in the diagnosis of central hypothyroidism | |
EP1566202A1 | Use of resistin antagonists in the treatment of rheumatoid arthritis | |
EP1529533A1 | Use of GH secretagogues in hypoxic-ischemic brain injury | |
WO03102240A1 | A method for identification of obese il-6 responsive patients | |
WO0182936A1 | Use of fucoidin in the treatment of arthritis | |
WO0136678A1 | A method to evaluate cytokine function |